Literature DB >> 29049725

CD11b and CD200 on Circulating Monocytes Differentiate Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.

Yousif Subhi1,2, Marie Krogh Nielsen1,2, Christopher Rue Molbech1,2, Akio Oishi3, Amardeep Singh1,4, Mogens Holst Nissen2,5, Torben Lykke Sørensen1,2.   

Abstract

Purpose: To investigate surface expression of CD11b and CD200 on circulating monocytes in patients with polypoidal choroidal vasculopathy (PCV).
Methods: This was a prospective case-control study of patients with PCV (n = 27), age-matched healthy controls (n = 27), and patients with neovascular AMD (n = 49). All participants underwent a comprehensive ocular examination. Fluorescein and indocyanine green angiography were performed in patients suspected of neovascular AMD or PCV. Polypoidal choroidal vasculopathy was angiographically categorized into those with a strong presence of a branching vascular network (BVN) (type 1) or with a faint/no clear presence of a BVN (type 2). Fresh venous blood was stained with fluorescent antibodies for flow cytometric analyses. We compared the percentages of CD11b+, CD200+, and CD11b+CD200+ monocytes between groups of diagnosis and between different angiographic subtypes of PCV.
Results: Overall, CD11b+ monocytes were both increased in patients with PCV and neovascular AMD. CD200+ and CD11b+CD200+ monocytes were increased in patients with neovascular AMD. An age-related increase in CD11b+CD200+ monocytes was absent in patients with PCV and neovascular AMD. Patients with PCV type 1 had significantly higher CD11b+, CD200+, and CD11b+CD200+ monocytes, whereas patients with PCV type 2 had levels similar to that in healthy controls. Conclusions: We found that PCV is immunologically heterogeneous with significant differences between angiographic subtypes. Increased CD11b+ and CD200+ monocytes in those with a strong presence of BVN indicate that BVN development may be associated with retinal injury and a VEGF-mediated process that is either reflected or propelled by systemic changes in monocytes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29049725     DOI: 10.1167/iovs.17-22479

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Upregulated CD200 in pre-retinal proliferative fibrovascular membranes of proliferative diabetic retinopathy patients and its correlation with vascular endothelial growth factor.

Authors:  Yaguang Hu; Anming Xie; Qiaochu Cheng
Journal:  Inflamm Res       Date:  2019-10-14       Impact factor: 4.575

2.  Anti-angiogenic and anti-inflammatory effects of CD200-CD200R1 axis in oxygen-induced retinopathy mice model.

Authors:  Yaguang Hu; Ting Wei; Shan Gao; Qiaochu Cheng
Journal:  Inflamm Res       Date:  2019-08-23       Impact factor: 4.575

3.  Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Mads Krüger Falk; Amardeep Singh; Thomas Vauvert Faurschou Hviid; Mogens Holst Nissen; Torben Lykke Sørensen
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

Review 4.  The role of lymphocytes and phagocytes in age-related macular degeneration (AMD).

Authors:  Verena Behnke; Anne Wolf; Thomas Langmann
Journal:  Cell Mol Life Sci       Date:  2020-01-02       Impact factor: 9.261

5.  The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Charlotte Liisborg; Helle Bach Søndergaard; Finn Sellebjerg; Torben Lykke Sørensen
Journal:  Immun Ageing       Date:  2019-08-15       Impact factor: 6.400

6.  Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.

Authors:  Charlotte Liisborg; Vibe Skov; Lasse Kjær; Hans Carl Hasselbalch; Torben Lykke Sørensen
Journal:  EClinicalMedicine       Date:  2021-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.